ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut

ALX ONCOLOGY HOLDINGS INC

GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.
Cash & equivalents $131.3M as of Dec 31, 2024; expects cash runway into Q4 2026 after ~30% workforce reduction.
ASPEN-06 Phase 2: evorpacept combo cORR 48.9% vs 24.5% control in HER2+ gastric cancer; median DOR 15.7 vs 9.1 months.
Leadership changes: appointed CBO, CMO, CFO; founder Jaume Pons steps down as President, becomes Senior Scientific Advisor.
Upcoming catalysts: ASPEN-03/04 HNSCC topline data Q2 2025; regulatory guidance on gastric cancer path Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.